Ardelyx reported strong third-quarter 2026 product revenue growth of 19% year-over-year, reaching $125.5 million, and maintained its full-year guidance for both products and operating expenses. This indicates continued operational strength and reinforces investor confidence in its growth trajectory, particularly for IBSRELA and XPHOZAH.
Ardelyx announced its third-quarter 2026 financial results, reporting a 19% year-over-year increase in product revenue to $125.5 million. The company also reiterated its full-year 2026 revenue guidance for IBSRELA and XPHOZAH, as well as its operating expense guidance, and maintained its long-term $1 billion revenue goal for IBSRELA. This news is positive for ARDX as it demonstrates continued commercial execution and financial stability, reinforcing investor confidence in its growth prospects. For traders, this suggests a potentially bullish short-term reaction due to exceeding revenue expectations and solidifying future outlook, with long-term implications tied to achieving the IBSRELA revenue target. The key opportunity lies in the sustained growth of its key products.